指南与共识神经肿瘤

MEK抑制剂治疗1型神经纤维瘤病表现:临床证据与共识

MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
指南 / 共识 · Neuro Oncol · 2022-01-01

1型神经纤维瘤病(NF1)的多种临床表现由RAS通路过度激活驱动,MEK抑制剂(MEKi)阻断RAS下游靶点。司美替尼近期获批用于儿童NF1不可手术的症状性丛状神经纤维瘤,成为美国、欧盟等地首个获批该适应证的药物。本综述汇总MEKi用于多种NF1相关表现(肿瘤与非肿瘤)的现有证据,讨论RAS通路过度激活相关遗传病(RASopathy)中的潜在用途,并给出专家组的临床使用共识推荐。

要点

  • 司美替尼已获监管批准用于儿童NF1不可手术的症状性丛状神经纤维瘤。
  • MEKi可能对多种其他NF1相关表现具有潜在获益。
  • 本文就MEKi的临床使用提供专家组共识推荐。

核心结论

  • MEKi可能对多种NF1相关表现具有潜在获益,专家组就现有MEKi的临床使用给出共识推荐。

研究设计与样本

  • 本综述汇总现有MEKi用于多种NF1相关表现的当前证据,涵盖肿瘤(神经纤维瘤、恶性外周神经鞘瘤、低级别胶质瘤、幼年型粒单核细胞白血病)与非肿瘤(骨、疼痛、神经认知)表现,并讨论RAS通路过度激活相关遗传病(RASopathy)中的潜在用途。

主要发现

  • 司美替尼近期获监管批准用于儿童NF1不可手术的症状性丛状神经纤维瘤,成为美国、欧盟等地首个获批该适应证的药物。
  • 多项近期发表及正在进行的临床试验显示,MEKi可能对多种其他NF1相关表现具有潜在获益。

关键数值与推荐

  • 专家组就现有MEKi的临床使用提供共识推荐。

临床怎么用

  • 专家组就现有MEKi的临床使用提供共识推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The wide variety of clinical manifestations of the genetic syndrome neurofibromatosis type 1 (NF1) are driven by overactivation of the RAS pathway. Mitogen-activated protein kinase kinase inhibitors (MEKi) block downstream targets of RAS. The recent regulatory approvals of the MEKi selumetinib for inoperable symptomatic plexiform neurofibromas in children with NF1 have made it the first medical therapy approved for this indication in the United States, the European Union, and elsewhere. Several recently published and ongoing clinical trials have demonstrated that MEKi may have potential benefits for a variety of other NF1 manifestations, and there is broad interest in the field regarding the appropriate clinical use of these agents. In this review, we present the current evidence regarding the use of existing MEKi for a variety of NF1-related manifestations, including tumor (neurofibromas, malignant peripheral nerve sheath tumors, low-grade glioma, and juvenile myelomonocytic leukemia) and non-tumor (bone, pain, and neurocognitive) manifestations. We discuss the potential utility of MEKi in related genetic conditions characterized by overactivation of the RAS pathway (RASopathies). In addition, we review practical treatment considerations for the use of MEKi as well as provide consensus recommendations regarding their clinical use from a panel of experts.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. de Blank PMK, Gross AM, Akshintala S, et al. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro Oncol. 2022. PMID: 35788692. doi:10.1093/neuonc/noac165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。